1. Home
  2. LOOP vs EQ Comparison

LOOP vs EQ Comparison

Compare LOOP & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loop Industries Inc.

LOOP

Loop Industries Inc.

HOLD

Current Price

$1.02

Market Cap

58.1M

Sector

Industrials

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.57

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOOP
EQ
Founded
2010
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.1M
57.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
LOOP
EQ
Price
$1.02
$1.57
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
73.4K
989.2K
Earning Date
01-15-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,112,000.00
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$41.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10901.98
N/A
52 Week Low
$0.85
$0.27
52 Week High
$2.29
$2.35

Technical Indicators

Market Signals
Indicator
LOOP
EQ
Relative Strength Index (RSI) 49.93 63.68
Support Level $0.95 $1.43
Resistance Level $1.04 $1.71
Average True Range (ATR) 0.07 0.19
MACD 0.02 0.03
Stochastic Oscillator 97.14 79.10

Price Performance

Historical Comparison
LOOP
EQ

About LOOP Loop Industries Inc.

Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: